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Pharmaceuticals are highly bioactive compounds now known to be wide-
spread environmental contaminants. However, research regarding exposure
and possible effects in non-target higher vertebrate wildlife remains scarce.
The fate and behaviour of most pharmaceuticals entering our environment
via numerous pathways remain poorly characterized, and hence our con-
ception and understanding of the risks posed to wild animals is equally
constrained. The recent decimation of Asian vulture populations owing to a
pharmaceutical (diclofenac) offers a notable example, because the exposure
route (livestock carcasses) and the acute toxicity observed were completely
unexpected. This case not only highlights the need for further research, but
also thewider requirement for more considered and comprehensive ‘ecophar-
macovigilance’. We discuss known and potential high risk sources and
pathways in terrestrial and freshwater ecosystems where pharmaceutical
exposure in higher vertebrate wildlife, principally birds and mammals, may
occur. We examine whether approaches taken within existing surveillance
schemes (that commonly target established classes of persistent or bioaccumu-
lative contaminants) and the risk assessment approaches currently used for
pesticides are relevant to pharmaceuticals, and we highlight where new
approaches may be required to assess pharmaceutical-related risk.
1. Introduction
In line with the expansion and changing age structure of the human population,
total global spending on human medicine has increased by approximately
$50 Bn yr21 since 2007, and will reach approximately $1.2 Tn by 2017 [1]. Large
developing nations, such as China, India and Brazil, are promoting swift
growth in their pharmaceutical manufacturing, human healthcare [1] and inten-
sive agricultural sectors. Increasing use of pharmaceuticals in human and
veterinary medicine has led to a concurrent rise in ‘medicated’ discharges to
the environment and this presents a significant challenge to risk assessors and
regulators charged with environmental protection. A wide range of drugs have
now been detected in multiple environmental compartments globally [2–6].
It can be argued that the likelihood of pharmaceuticals causing widespread
acute effects in wild higher vertebrates is low. This is because extensive safety test-
ing is conducted during the development of modern human and veterinary drugs
and also because of the existence of regulatory and environmental protection
frameworks. However, a number of significant weaknesses remain with respect
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Figure 1. Pathways of pharmaceutical releases to freshwaters. (Online version in colour.)
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siderable testing of pharmaceuticals on some mammal species,
there is less on birds and data on pharmacokinetics and thera-
peutic doses in birds are limited. What data there are suggest
that there can be substantial differences in sensitivity and
toxicity between birds and mammals and, in fact, between
different mammal species [7–10]. In addition, the potential for
bioaccumulation or bioconcentration and resultant elevated
exposure in higher wildlife is not well characterized, particu-
larly for terrestrial systems [11,12]. Risk assessments also focus
on single pharmaceuticals, whereas wildlife will typically be
exposed to complex mixtures, and our understanding of how
pharmaceuticals interact with each other and affect toxicity is
limited [13,14]. Finally, regulatory frameworks that monitor
and restrict pharmaceutical emissions to the environment are
often absent or ineffectual in many developing countries [15]
and, even when in place, there may be a need to upgrade treat-
ment processes (at sewage treatment plants (STPs) for example)
to adequately curtail emissions of pharmaceuticals to the
environment [16,17].
Significant adverse effects in terrestrial and aquatic
organisms caused by pharmaceuticals have demonstrated
inadequacies in current risk assessment and regulatory pro-
cesses. Two of the most notable cases that have caused
global concern are (i) the near extirpation of Gyps vulture
populations in large parts of Asia following exposure to
non-steroidal anti-inflammatory drugs (NSAIDs) [18–20]
and (ii) the feminization of wild male fish from exposure to
synthetic oestrogen 17a-ethynyloestradiol (EE2), a common
ingredient in the human contraceptive pill [21,22], although
it is not known whether such endocrine effects likewise
occur in higher aquatic vertebrates. Furthermore, pharmaceut-
icals are designed to be highly bioactive, often for prolonged
periods at low doses. Therefore, although severe adverse effects
on wildlife have been detected, any effects of pharmaceuticals
on wild higher vertebrates are more likely to be chronic and
subtle. Such effects will be difficult to detect and quantify or
to attribute to a particular input. However, even basic monitor-
ing data on exposure and effects of pharmaceuticals in higher
wildlife are scarce [23].
Here, we review the current state of knowledge regarding
pharmaceutical contamination and effects in wild higher ver-
tebrates, specifically birds and mammals. There are few data
for birds and mammals but, given the severe impact of diclo-
fenac on Asian vultures, our aim is to draw attention to
potentially relevant exposure pathways. We examine which
exposure-mediating factors are incorporated in current risk
assessment processes and consider how exposure of wildhigher vertebrates to pharmaceuticals may best be detected.
The question underpinning this review is: can the current
systems used to detect exposure and assess risks to higher
vertebrates from chemicals (such as pesticides) be applied
to pharmaceuticals? Unless relevant to specific food chain
pathways (i.e. for piscivorous species), we do not consider
exposure in wild fish as this is covered comprehensively else-
where [4,13,21,22,24,25], nor do we review laboratory-based
exposures aimed at detecting specific compound–species
effects. Instead, we focus on environmentally relevant field
exposure situations, primarily for birds and mammals, in
freshwater and particularly terrestrial habitats worldwide.2. Key exposure sources and pathways
Concern over the release of pharmaceuticals to the environment
has, until recently, focused on freshwaters, reflecting the fact that
human medicines almost invariably end up in aquatic systems
because of urinary and faecal excretion of prescription and rec-
reational drugs, and improper disposal of old medication [26].
Pharmaceuticals can enter freshwater systems through a
number of pathways (figure 1), the principal routes being the
discharge of liquid waste (domestic sewage, hospital or indus-
trial effluent) into aquatic habitats [16,27]. Research has tended
to centre on municipal STPs [16,28,29], principally in Europe
and North America, on hospitals [28,30] and on drug manufac-
turing facilities [15,29,31] which emit less volume but more
concentrated effluent. Aquaculture has also attracted attention
as a source of pharmaceutical inputs to freshwaters [32,33].
Untreated domestic, municipal and industrial sewage
effluent containing drugs can also enter freshwater via
misconnections, failed sewage pipework, combined sewer
overflows, septic tanks, or owing to a complete absence of
sewer and STP infrastructure. Recent data suggest that even
in high-income countries about 30% of wastewater is dis-
charged untreated, a figure that increases to about 92% in
low-income countries [34,35]. The standards for solid waste
management likewise vary considerably around the world
[36]. Pharmaceuticals are now a known component of landfill
leachate and can affect groundwater quality [37], but thewider
impacts of leachate on freshwater resources and food webs
have not been investigated. Landfill engineering is usually
absent in most low-income countries and disposal sites are
simply open dumps, with little to no leachate control or miti-
gation. In contrast, sanitary landfills in other regions (i.e. in
Europe, North and South America) may be fully lined and
engineered to prevent leachate impacting freshwater resources
[36]; leachate treatment plants may also be used.
Table 1. Potential terrestrial exposure pathways associated with different processes/practices.
process/practice possible exposure route/risk
landfill/municipal solid waste disposal
disposal of waste medication
— direct ingestion of medication/leachate by scavengers
— indirect ingestion by insectivores (e.g. birds/bats) consuming insects feeding on waste/leachate
— contamination of local freshwater resources and land by leachate containing drugs
animal waste disposal
disposal of ‘medicated’ animal carcasses
— carcass may contain medication administered before death—ingestion by scavengers (or carnivores)
— indirect ingestion by insectivores (e.g. birds/bats) consuming insects feeding on medicated carcasses
— sustained release bolus (long duration medication—as tablets) may be present within carcass
digestive tract
liquid waste processing
STP treatment of ‘medicated’ effluent
— STPs ‘attract’ certain species, e.g. insectivores or aquatic birds at trickling filters or tertiary treatment/
polishing lagoons (respectively)
— direct ingestion of wastewater and/or long-term dermal exposure in lagoons (aquatic birds and
mammals)
— indirect ingestion by insectivores (e.g. birds/bats) consuming invertebrates feeding on effluent (e.g. at
trickling filters) or emerging from lagoons
— potential bioaccumulation and food chain/trophic transfer within lagoon ecosystems
applying manure, slurry or STP biosolids/
effluent to land
re-use of ‘medicated’ waste in agriculture
— potential for persistence and/or bioaccumulation of certain compounds in soil and soil invertebrates
— food chain/trophic transfer in agricultural ecosystems
— direct ingestion by birds/mammals
— indirect ingestion by insectivores (e.g. birds/bats) consuming soil/aerial invertebrates
livestock/poultry production
‘medicated’ faeces deposition
— livestock/poultry receiving medication generate contaminated faeces and urine
— direct ingestion by soil and aerial invertebrates
— indirect ingestion by insectivores (birds/mammals, etc.)
— contact with residues in hair, wool, feathers and other material used as nesting or ingestion of this material
— direct ingestion by coprophagous vertebrates
— risk of high exposure if sustained release bolus (long duration medication—as tablets) in use
— intensive outdoor operations (e.g. feedlot CAFOs) may pose a particularly elevated risk
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tat has received far less attention compared with freshwaters.
In general, terrestrial inputs exist where liquid or solid waste
contaminated with drugs is deposited on land (table 1). Point
sources of emissions include carcass dumps and landfill sites
as well as STPs and other wastewater holding areas/lagoons
[38] that may provide habitat or substrate for the prey of
terrestrial predators. Agriculture is the other major source
by which pharmaceuticals are likely to be emitted to the
terrestrial environment, although inputs may lead to simul-
taneous contamination of freshwater habitats via surface
run-off and groundwater leaching [39–41]. Industrial agricul-
tural systems, such as concentrated animal feeding operations
(CAFOs), undertake confined, highly intensive rearing of ani-
mals in areas without vegetation (indoors on concrete or
outdoors on un-vegetated feedlots) and are an increasingly
common means in the USA and beyond of meeting global
demand for food. The operations rely heavily on the constant
administration of veterinary medication (antibiotics, steroids,
growth promoters and antiparasitics) andmay represent impor-
tant sources of environmental contamination [42–44]. More
diffuse environmental inputsmayarise from fertilizationof agri-
cultural land with manure, slurry, biosolids and STP effluent.
Non-intensive livestock rearing may likewise result in diffuse
emissions through processes such as direct excretion of veterin-
ary products by animals, shedding/moulting of fur, feathersand other similar material that may contain residues of veterin-
ary products, and through the death of medicated livestock in
areas where carcasses remain un-retrieved.
Exposure pathways for higher vertebrates may be directly
through ingestion of and contact with contaminated water,
through herbivory of contaminated forage, secondary exposure
through predation of contaminated invertebrates and lower
vertebrates, and direct exposure through coprophagy. While
the potential impact of pharmaceuticals on invertebrates, par-
ticularly coprophagous insect communities, has received
intense scrutiny [45–47], the exposure risks to higher ver-
tebrates within food webs largely remain to be investigated
[48]. For aquatic birds and mammals, foraging around STPs
is arguably the most important exposure route. Potential
exposure routes for terrestrial higher vertebrates are perhaps
more diverse and summarized in table 1.3. Factors considered in risk assessment that
mediate exposure and effect
In general, there is lack of guidance when considering the key
factors affecting the exposure of wildlife to pharmaceuticals.
Given this, it may be useful to consider the existing, very
well developed, approaches used for estimating exposure
of birds and mammals to another group of anthropogenic
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regulatory approaches for estimating acute and chronic
risks to birds and mammals from PPPs involve calculating
toxicity : exposure ratios (TERs). These estimate how much
the toxic dose (for example, an LD50) exceeds the estimated
exposure [49]. Broadly equivalent approaches are used else-
where and for other chemicals, although they may use
other ratios such as a risk characterization ratio (RCR)—
essentially, the inverse of a TER. A major factor when calcu-
lating a TER or RCR is estimating the exposure term. This
involves accounting for various factors that may modify the
uptake of PPPs by organisms. These are considered here to
examine whether similar factors are equally likely to
modify the risk of exposure to pharmaceuticals.
It is currently assumed that the only significant exposure
route for PPPs in birds and mammals is through ingestion
(oral exposure). Risk assessments are tiered, and an initial
screening tier uses relevant acute or chronic toxicity data, ‘indi-
cator’ species and worst-case estimates of exposure. If a PPP
fails the screening, first tier assessments are conducted using
‘generic focal species’ and more realistic estimations of dietary
exposure for acute and reproductive risk. These include
standardized approaches to assess risk from endocrine-
disrupting chemicals (EDCs), from metabolites, and from
bioaccumulation; three bioaccumulation food-chain scenarios
are used (earthworm to earthworm-eating birds and mam-
mals; fish to piscivorous bird/mammal; biomagnification in
food chains). Application of such approaches may be particu-
larly important for pharmaceuticals as the majority are
ionizable and, by their nature, readily metabolizable. Sub-
sequent higher test tiers for PPPs use specific focal species
and typically employ a range of refinement options tailored
towards realistic exposures for those species. Toxicity endpoints
can also be refined. For example, phase-specific reproductive
endpoints can be used to relate timing of exposure to that of
reproductive cycles in birds and mammals [50,51].
While the general framework for assessing PPP risk may be
applicable to pharmaceuticals, some of the refinements used to
reduce exposure from worst case to more realistic values may
not always be appropriate. Such refinements include (i) esti-
mating food intake rate for focal species based on allometric
equations of daily energy expenditure (DEE) and water flux
[52,53], (ii) bioaccumulation, and (iii) the fact that only a pro-
portion of ingested food is contaminated. Some scavengers,
for example, actively seek and feed communally on carcasses
and so it is possible that they predominantly feed on sick and
medicated animals. Hence refinement of risk based on an
assumption that only a proportion of ingested food is contami-
nated may not be appropriate. Scavengers also gorge at
carcasses and can eatmore at one feed thanwould be predicted
just from estimates of intake based on DEE requirements [54].
Reliance on such estimates may therefore underestimate
exposure. Scavengers may also be selective in terms of the tis-
sues they consume. Preferential feeding on stomach contents
and soft tissues such as liver, kidney and heart is likely to
increase exposure and risk [55] and may occur at multiple
trophic levels, thereby enhancing bioaccumulation along food
chains. Clearly, oral exposure risk assessments need to account
for the pharmacokinetics of the compound, although for
pharmaceuticals even the most basic parameters such as
half-lives are inadequately characterized in higher vertebrate
wildlife species. Risk assessments also need to consider the
feeding preferences and general ecology of the species ofinterest because these may alter and even enhance exposure
risk. This is true for PPPs as well as for pharmaceuticals,
although refinement stages for PPPs are usually predicated
on the expectation that they will reduce (rather than enhance)
estimated risk.
PPP risk assessments for birds and mammals do not cur-
rently account for dermal or inhalation exposure, although it
has been argued that dermal uptake may sometimes be a sig-
nificant exposure route [56], and the potential for inhalation
during spray applications is clear [57]. Dermal exposure to
PPPs, and equally pharmaceuticals, may arise from contact
with contaminated water, while moving across contaminated
soil or while dust/puddle bathing. Species such as small
mammals, that not only forage on contaminated soil but
also burrow into it, may be at particular risk, as may aquatic
vertebrates that come into contact with contaminated water.
The potential for inhalation exposure of pharmaceuticals by
higher wildlife is less obvious, except perhaps for dust inhal-
ation associated with treatments in intensive livestock rearing
[58]. The Environmental Protection Agency in the USA is
developing models for assessing PPP exposure via both
dermal and inhalation routes in birds [59] and these may
prove a useful starting point should either or both routes be
considered important for pharmaceuticals.
As well as considering whether approaches used in PPP
exposure assessments can be applied to pharmaceuticals, it
is also relevant to ask whether the TER toxicity endpoints
are appropriate when assessing risks from pharmaceuticals.
Current toxicity assessments used in PPP risk assessments
for birds and mammals use endpoints that are directly related
to mortality and reproduction. These are obviously two key
parameters that directly impact population dynamics and
can be assessed to some extent in laboratory tests. However,
the current range of toxicity endpoints used for PPPs has
been criticized as too limited for birds but overabundant
and too detailed for mammals; the consequence is that it is
often difficult to extrapolate realistically from the laboratory
to the field [60]. If pharmaceuticals are indeed most likely
to have subtle physiological, immunological, behavioural
and neurological effects in wild higher vertebrates, such
effects could have both direct and indirect impacts on long-
term survival and on behavioural phases of the reproductive
cycle. Some or possibly many such effects may commonly go
undetected using the standardized PPP tests currently under-
taken in artificially controlled conditions on laboratory-bred
species. There may well be a need to review likely effects
associated with the most prevalent classes of pharmaceuticals
released to the environment and to develop new toxicity end-
points that are both appropriate to detecting such effects and
are relevant in terms of impacting populations. Any such devel-
opments would be equally likely to increase the robustness of
risk assessments for PPPs and all other chemicals.4. Evidence of exposure and effects of
pharmaceuticals on higher wildlife
Few field data have been gathered on exposure to, and effects
of, pharmaceuticals in higher vertebrate wildlife. The studies
conducted to date can be broadly separated as those consid-
ering impacts associated with (i) STPs and freshwater, and
(ii) terrestrial systems.
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water irrigation and sewage treatment plants
The use of sewage water for irrigation poses a potential risk
to wildlife. We are not aware of specific studies on wild
higher vertebrates but there have been incidences of hyper-
oestrogenism in cattle fed alfalfa that was irrigated with
untreated sewage water containing phytoestrogens [61]. Inter-
estingly, studies on alfalfa that was irrigated with water
containing oestrogenic contaminants (17b-oestradiol and oes-
trone) concluded that alfalfa growth was increased when
irrigatedwithwater containing lower oestrogen concentrations
and suppressed when thewater contained high concentrations
[62]. This suggests that the effects of oestrogens can and do
cross between plants and animals, but no details were dis-
cussed on the concentrations of oestrogens that resulted in
variable growth of the alfalfa, or on the amounts of affected
alfalfa that were consumed by the cattle.
Several studies have now investigated risks to birds feed-
ing on invertebrates exposed to STP effluent at trickling
filters. These have indicated that invertebrates living on and
emerging from STP trickling filters have the potential to
bioaccumulate/bioconcentrate certain pharmaceutical EDCs
[63,64]. Adult male starlings (Sturnus vulgaris) experimen-
tally exposed to environmentally relevant levels of various
EDCs displayed altered immune function and changed
development that affected behaviours such as singing [65];
reduced growth and depressed immunocompetence were
also observed in the nestlings [66]. Additional species of ver-
tebrate wildlife likely to be exposed through the food web
include those that take insects on the wing (such as swallows
(Hirundinidae), swifts (Apodidae) and bats (Chiroptera)).
The population-level consequences of such exposure, and
the specific role played by synthetic pharmaceuticals as
opposed to natural and non-pharmaceutical-EDCs, remain
to be elucidated.
With regard to general contamination of freshwater habi-
tats, informative data are now available on the impacts of
certain pharmaceuticals and pharmaceutical-EDCs, such as
EE2, in some species, particularly fish [22,67–69]. Published
research on exposure and effects in mammals or birds that
share the same freshwater habitat or that could feed on
medicated prey is, however, extremely rare. A study to evalu-
ate bioaccumulation potential of pharmaceuticals in the diet
of ospreys (Pandion haliaetus), a well-known sentinel of
environmental pollution, has been reported to date as a
conference abstract [70]. This study used an integrated mod-
elling approach to estimate potential pharmaceutical doses
to nestling ospreys and also measured the concentrations of a
range of pharmaceuticals in water, prey fish and nestling
osprey plasma to confirm the validity of the model. Of 18 phar-
maceuticals detected in water, only the antihypertensive
diltiazem was detected in nestling plasma; levels were below
the human therapeutic concentrations in all 47 nestlings that
were analysed. Studies on another freshwater sentinel, the
Eurasian otter (Lutra lutra), indicates that oral and/or
dermal exposure to diclofenac and ibuprofen is taking place in
the UK [71]. Renal lesions observed during carcass necropsies
have prompted recommendations that future studies examine
exposure of otters to nephrotoxic agents such as NSAIDs
[72]. In general, top predators are likely to be most susceptible
to pharmaceuticals that bioaccumulate and bioconcentrate
in prey.(b) Impacts on higher vertebrates associated
with terrestrial systems
The clearest example of widespread exposure and effect
relates to the impact of the NSAID diclofenac on vultures,
as described in detail in this special issue [18]. Carcass
dumps are now well recognized as a critical exposure path-
way for pharmaceuticals to vultures in Asia [18], and there
are current similar concerns about the susceptibility of scav-
engers (vultures and kites) to antibiotics (and to NSAIDs
and antiparasitics) when feeding at muladares (small carcass
dumps) in Spain. There have been some studies that indicate
the occurrence of various adverse effects on egg develop-
ment, immunocompetence and disease prevalence, but all
relevant data regarding these Spanish carcass dumps have
now been retracted from publication. As such, the real picture
in Spain specifically remains unclear. Further investigation of
the potential for exposure and effects of pharmaceuticals in
vultures in Spain (a very important stronghold for vultures
in Europe) and in Africa is merited. Studies in Spain are par-
ticularly warranted given: (i) the 2013 approval of diclofenac
for veterinary use in that country [73], (ii) the fact that some
carcasses provided at muladares, managed feeding stations
and at captive breeding and rehabilitation centres, are
known to originate from intensive operations such as large
pig rearing facilities where animals are heavily medica-
ted, and (iii) a concern that risk assessments seem poorly
developed for scavengers, as already highlighted in §3.
Antiparasitics are also widely used on livestock making
them, in effect, pharmaceuticals. Many, such as organophos-
phates, carbamates and pyrethroids, were developed as
agrochemicals and so, unlike most pharmaceuticals, their
adverse effects in non-target wildlife are relatively well
described. Antiparasitic applications of famphur, fenthion,
diazinon and propetamphos to lambs, cattle and pigs have
been linked to bird of prey poisonings in Canada, USA and
the UK [74]. Because of concerns about infectious diseases
such as foot and mouth disease virus, carcasses of small dom-
estic ruminants are no longer left to be ‘incorporated into
nature’, and slaughterhouse remains are meant to provide safe
food sources for vultures. Lower limbs of lambs collected
from a Spanish slaughterhouse have been shown to contain
up to 618 ng g21 of diazinon and 1008 ng g21 of cypermethrin
[52]. These portions of carcasses are currently being offered at
vulture feeding stations in the Pyrenees.Although the estimated
dose of diazinonwas considered below the acute avian LD50 for
these compounds, chronic effects (induced hypothermia or
behavioural impairment [75]) cannot be ruled out.
Scavengers can also be poisoned by feeding on euthanized
animals. Residues of barbiturates in carrion have been found to
exceed the lethal dose for a spectrum of scavengers [76,77], and
there have been reports of secondary barbiturate poisoning
[78]. In some parts of the USA, landfills are legal areas for
dumping the carcasses of euthanized animals, and free living
bald eagles (Haliaeetus leucocephalus) and golden eagles
(Aquila chrysaetos) are known to have died of barbiturate poi-
soning; in northern climates, late winter—early spring has
been themost common time to find poisoned raptors and scav-
engers as carcasses are thawing during a time of low food
availability [79]. While poisoning of large-bodied animals in
areas with moderately high human populations is likely
to be detected, as on Vancouver Island (Canada), where
29 bald eagles were intoxicated after feeding on a euthanized
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may not be detected. Furthermore, incidents involving smaller,
less conspicuous animals are more likely to go unnoticed, as is
evident from mortality incident monitoring schemes; for
example, submissions of mammals to the UKWildlife Incident
InvestigationSchemearedominatedby large species like red fox
(Vulpes vulpes) and badger (Meles meles) [80]. Such biases mask
the true extent of exposure and poisoning of wildlife by PPPs,
pharmaceuticals or any other toxicant.
There is also a notable dearth of information regarding
risks to terrestrial wildlife fromdiffuse pharmaceutical sources,
such as fertilization of agricultural landwith slurry and biosol-
ids. Studies on agricultural animals suggest potential exists for
effects. Testosterone and oestrogen, used as growth promoters
in chicken production have, for example, caused endocrine dis-
ruption in cattle fed rations containing chicken manure. One-
quarter to one-third of heifers fed chicken manure silage did
not reach puberty and animals already past puberty developed
cystic ovaries and stopped cycling after onemonth of exposure
[81]. The likelihood of such effects occurring in wildlife would
depend, among other things, on how much feeding took place
in a fertilized area and the persistence of pharmaceuticals
in soil. The one specific study that we are aware of has again
only been reported to date as a conference abstract [82].
In a seven year experimental study in which triclocarben-
and triclosan-contaminated biosolids were applied to fields,
concentrations of these two antimicrobials were measured in
biosolids, soils, earthworms and the eggs of American kestrels
(Falco sparverius) and European starlings (S. vulgaris). Kestrel
and starling egg morphometrics and nesting success were
also tracked. The antimicrobials were detected in biosolids,
soil, earthworms and the eggs of both avian species. Concen-
trations were higher in samples from the experimental than
the control site for starling eggs, soil andworms, but not kestrel
eggs. Nesting success was lower on the experimental than con-
trol site for kestrels but not starlings. This study provides
evidence that antimicrobials from biosolids can be transferred
to eggs of secondary and tertiary consumers and begs more
research on the food-chain transfer and biological impacts of
pharmaceuticals in terrestrial higher vertebrates.5. How are exposure and effects detected in
wildlife for other contaminants of concern?
Once released into natural habitats, pharmaceuticals can be
considered just another class of environmental contaminant.
While few monitoring studies have examined exposure and
effects of pharmaceuticals in higher wild vertebrates, various
programmes currently investigate uptake and effects of toxic
metals, pesticides, biocides and organic pollutants in higher
vertebrates. Some primarily measure exposure (and limited
effects), whereas others are specifically tailored to determine
effects, typically mortality, and their cause [83–86].
A number of schemes that focus on vertebrate exposure to
pollutants also measure contaminants in dietary items. This
approach forms the basis for regulatory assessment of risk, as
described in §3, but there are challenges in terms of detecting
and measuring exposure to diffuse pollutants. This is because
environmental concentrations of such compounds may often
be low with typically high spatio-temporal variability [87].
An alternative is to measure contaminants in sentinel species
that are representative of particular trophic pathways. Suchspecies are often apex predators that can bioaccumulate, and
in some cases bioconcentrate, pollutants. Tissue concentrations
then rise above analytical detection limits and this can be critical
in terms of clearly identifying the presence and effects of con-
taminants within a system. A range of predatory birds and
mammals have been used as sentinels [84,88,89]. Typically
long-lived species with large foraging ranges, sentinel species
can integrate exposure both temporally and spatially, thereby
smoothing small-scale variability and aiding detection of
large-scale and long-term trends. Furthermore, large vertebrate
predators are often seen as charismatic species. Data regarding
such species tend to excite public and stakeholder interest, and
this can be importantwhen the discovery and collection of dead
wildlife relies on citizen science, hunters or other representative
groups within a community [90–92].
The exposureof highervertebrates to a rangeof contaminants
has typically been demonstrated using a residue monitoring
approach. Tissue residues are by definition indicative of the
bioavailable fraction of the environmental concentration and
the favoured types of samples include various body tissues,
blood, eggs, hair, feathers and other substances such as preen
oil [84,88–91]. Exposure studies can be critical in identifying
key factors that drive exposure [93–96], can relate measured
residues to levels known to cause adverse effects [97], and
measure effects directly using biomarkers [98–101]. We are
not aware of any current long-term wildlife monitoring
schemes that target pharmaceutical residue analysis, though
pleas have been extended [23,48].
Some national monitoring schemes have an effects-based
approach, particularly regarding poisoning [83,85]. Such
mortality incident monitoring schemes are intended to detect
significant adverse effects, ostensibly mortality, caused by
authorized PPPs and, in some cases, other approved toxicants.
Effects brought to light by such schemes would often not
have been foreseen during the risk assessment and author-
ization process and their occurrence in turn may trigger
review of authorizations and amendments to risk assessment
processes. Such schemes are also used to detect and investigate
the misuse and illegal abuse of pesticides and have, for
example, identified significant predatory bird and mammal
mortality owing to a wide range of poisons, chemicals,
pesticides and biocides [74,85,102].
The key question here is whether exposure and mortality
incident monitoring schemes can be used to accurately con-
sider exposure/effects of pharmaceuticals in wild higher
vertebrates, or are bespoke stratagems needed? Detection of
mortality alone is relatively crude and, as indicated in §4,
pharmaceuticals may well induce more subtle changes in
exposed wildlife. Given the general absence of data, deter-
mining the current prevalence and extent of exposure in
wildlife would arguably be the first priority. Monitoring
schemes that rely upon apex predators as sentinels may
best detect exposure to pharmaceuticals that have high bioac-
cumulation potential. Such schemes should perhaps focus
pharmaceutical monitoring on species that are insectivorous
and/or vermivorous in terrestrial systems, piscivorous in
freshwater habitats or general scavengers as these three path-
ways are the likely major exposure routes; this would also be
compatible with monitoring for pesticide exposure [74].
Development of techniques to measure trace residues of phar-
maceuticals in non-destructive samples, such as feathers,
hair, wool and faecal matter [43,48,54,71] can facilitate moni-
toring without capture of, or disturbance to, animals, and
rstb.royalsocietypublishing.org
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that have short half-lives and would be unlikely to be
detected in physiologically active tissues. For example, feath-
ers and wool can be gathered from nest sites and hair can
be collected using hair tubes (small mammals) and hair-
snagging stations (large mammals). Such samples can be
analysed for DNA (to distinguish species/individuals) and
chemical residues. These techniques may be particularly
important when species are secretive and hard to capture,
and can be used to gather large numbers of samples at rela-
tively low cost. They are already being used to monitor
exposure and, in some cases, effects associated with pesti-
cides and pollutants [84,103] and are likely to be equally
useful for monitoring pharmaceuticals [48]..R.Soc.B
369:201305706. Discussion
It is often difficult to predict the complete life cycle of a chem-
ical in the environment at a national or regional scale because of
economic, social and cultural differences. However, if pharma-
ceuticals are to be developed for use in a safe manner, the
possibility that they may reach non-target wild higher ver-
tebrates should be considered. In the European Union (EU)
for example, active PPP ingredients are authorized by a
pan-EU body (the European Food Safety Authority), but prod-
uct authorizations and associated risk mitigation strategies
remain the preserve of national entities. Such an approach
can incorporate regional life cycle assessments and risks
factors and implement associated mitigation. Regulations for
pharmaceuticals should work in a similar manner.
The impact of diclofenac on vultures in Asia in particu-
lar has demonstrated the need for national or regional
ecopharmacovigilance strategies to support regulatory risk
assessment. The existence of exposure and mortality incident
monitoring schemes in some regions, such as Western Europe
and North America, provides a good platform for ecophar-
macovigilance, although programmes are needed elsewhere.
Information on the national/regional scale of pharmaceutical
use is required if monitoring schemes are to establish
adequate analytical screening methods. These should be
linked to modelling approaches that are designed to identify
which compounds/classes of compounds are most likely to
persist in the environment and bioaccumulate, thereby facili-
tating the targeting of analytical effort. Exposure monitoring
schemes that use apex predators will be best suited to moni-
toring less polar, more persistent compounds, but may need
to include additional sentinel species that scavenge or feed on
invertebrates, the latter representing an exposure pathway
that is relatively poorly covered by existing schemes [84]. In
contrast to exposure monitoring programmes, mortality inci-
dent monitoring schemes usually examine mortalities in a
wider range of species, including those from lower trophic
levels. Although we have argued that mortality is a crude
means of assessing any impact of pharmaceuticals, mortality
monitoring schemes could facilitate ecopharmacovigilance by
greater use of the carcasses of animals they receive. This
would require a widening of remit, so that schemes under-
took (or made carcasses available for) screening of samples
to determine if there has been exposure to pharmaceuticals;
currently, analyses are often limited to compounds suspected
to be the cause of death and wider analyses are not under-
taken. Such engagement, particularly using species fromlower trophic levels, would be especially useful for investi-
gating exposure (and possibly pinpointing inputs) to less
persistent and less bioaccumulative compounds that are un-
likely to be detected by monitoring schemes using apex
predators. Successful national and regional ecopharmacovigi-
lance would best be served by coordination between different
schemes, even though they may have different aims and
stakeholder perspectives. Models to improve collaboration
and knowledge exchange between diverse exposure and
mortality monitoring schemes already exist and have
proven successful [104].
This review has also highlighted that, while existing gen-
eric risk assessment procedures for chemicals should be
applicable to pharmaceuticals, major modifications may be
necessary. Exposure scenarios may not adequately assess cer-
tain critical pathways, such as those applicable to scavengers.
The toxicity endpoints, and in some cases, the test species, cur-
rently used in risk assessment are also unlikely to detect the
more subtle chronic effects that pharmaceuticals may exert
on wildlife. Developing new sensitive tests and endpoints,
and demonstrating their value for assessing likely impacts on
populations, is challenging, but such work would benefit risk
assessment not only for pharmaceuticals, but also PPPs and
other environmental contaminants generally.
A slightly tangential, but highly relevant issue related to
drugexposure inhigherwildlife is that of exposure to antibiotics,
antibiotic-resistant genes and multi-drug-resistant microbes.
Antibiotic-rich effluents are of particular concern as they have
been shown to promote the development of antibiotic-resistant
microbes in the environment, which could have unpredict-
able and wide reaching consequences for human and wildlife
health [15,105]. Antimicrobial drug use is also especially
common in intensive livestock operations, including CAFOs
[38,44], and residues may enter the terrestrial environment by
various routes. Furthermore, inhalation of CAFO aerosols may
facilitate the transfer of multi-drug-resistant bacterial pathogens
from farmed animals to exposed humans [42,106], highlighting
thepotential importance of inhalationpathways,whichhavenot
previously been considered vis a vis the impacts of pharmaceuti-
cals on the environment.Overall, theprimary concern regarding
antibiotics is not so much direct effects on wildlife, but rather
that wildlife could play a role in the transfer of antibiotic-
resistant microbes between humans and the environment
[105–110]. While worthy of note, a comprehensive review of
this complex, and likely increasingly important, issue is outside
the scope of this paper.
In conclusion, the increasinguse ofmedicationbyaburgeon-
ing human population and its agricultural livestock ensures an
ongoing and likely increasing release of pharmaceuticals to the
environment. This, coupled with other pressures, such as
human demographic change leading to the development of
super-cities, increased intensification of food production and
climate-induced hydrological changes, may alter our ability to
limit, regulate and dilute pharmaceutical discharges to the
environment [111]. It is notable that two of the most import-
ant wildlife ecotoxicological cases recently associated with
environmental pollutants (widespread vulture declines and
feminization of fish) are directly related to the use and disposal
of pharmaceuticals rather than to other drivers. Existing frame-
works and platforms can be used to help us improve our
knowledge of current and future environmental concentra-
tions and effects of pharmaceuticals. The development and
application of that knowledge is now a priority.
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